Dr Reddy’s Q2 profit down 60% to Rs. 31 cr

NEW DELHI, OCT 25:  

Dr Reddy’s Laboratories today reported a decline of 60.12 per cent in consolidated net profit for the September quarter at Rs. 30.89 crores, mainly because of a drop in sales in Venezuela and North America.

The company had posted a net profit of Rs. 77.47 crore in the July-September quarter of the previous fiscal, Dr. Reddy’s Laboratories (DRL) said in a filing to BSE.

DRL’s total income from operations on a consolidated basis was down 10.05 per cent to Rs. 361.63 crore as against Rs. 402.07 crore in the corresponding quarter last fiscal.

“All major businesses have shown sequential improvement over the previous quarter with revenues up 11 per cent and EBITDA 61 per cent. We have made progress on remediation efforts and continue to work on addressing concerns of the regulator,” DRL’s Co-chairman and CEO G. V. Prasad said.

Its total expenses were up 4.49 per cent to Rs. 325.15 crore as against



Rs. 311.17 crore last year.

“The gross profit margin declined by 56 per cent ... primarily on account of lower sales due to increased competitive intensity in some of our key molecules in the US,” the company said.

“Revenues from the global generic segment was at Rs. 29 billion, a year-on-year decline of 12 pe cent; decrease primarily on account of the lower contribution from North America and loss of sales from Venezuela,” it added.

In the first half of the current fiscal, DRL’s consolidated standalone net profit was down 67.48 per cent at Rs. 46.24 crores as against Rs. 142.22 crore in the six-month period a year ago.

Its total income in the first half of the current fiscal was also down 11.96 per cent to Rs. 686.10 crore compared to Rs. 779.35 crore in the same period last year.

Shares of DRL were trading at Rs. 3,115.60 on BSE during the morning trading hour, up 0.84 per cent from the previous close.